Anthony J. Giovinazzo

Biography

Anthony J. Giovinazzo has over of thirty-eight years of professional experience, including seven years as an international corporate tax specialist and eight years in investment banking and private equity. For the last 23 years he has solely focussed on the discovery, development and commercialization of neurodegenerative disease therapeutics. Since October 2016 he has been the President and CEO of Sunovion CNS Development Canada ULC., a successor company to Cynapsus Therapeutics Inc., which was purchased by Sunovion Pharmaceuticals, a member of the Dainipon Sumitomo Pharma group of Japan. He was President, CEO and a Director of Cynapsus Therapeutics from 2009 to 2016 and one of the three original inventors and patent holders of the company’s Parkinson’s focussed technology, leading the successful development of APL 130277 (a sublingual strip of apomorphine) through to late stage Phase 3 studies. In addition, he led the company’s up-listing from the TSX Venture exchange to the TSX and then the NASDAQ, attracting bulge bracket investment banks and some of the largest institutional life science investors in the USA. Anthony is the co-author of several peer reviewed papers and author of several papers on strategic and financing issues in the biopharmaceutical industry. He is a Chartered Director and Audit Committee Certified, both from The Directors College of Mc Master University, Hamilton Canada. Anthony obtained his MBA from IMD, Geneva Switzerland ; a Graduate Certificate Studies in Canadian Law from Osgoode Hall Law School, York University, Toronto; and his BA in Economics and Accounting from McMaster University.

Research Interest

investment banking and private equity.